Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Okinawa Buys Three Genome Analyzers To Boost Biopharma Research

This article was originally published in PharmAsia News

Executive Summary

With financial support from the prefectural government, the Okinawa Health Biotechnology Research and Development Center has invested ¥0.29 billion and purchased three genome analyzers in an effort to speed up genetic analysis and boost research efficiency. A single facility with three such high-speed systems is a rarity and is the largest of its size in Japan. The move is aimed to improve biopharma research in Okinawa and provide a preferred research destination for pharmaceutical companies. Okinawa is known for its unique subtropical location and the population with the highest longevity in Japan. The Prefecture has actively promoted biopharma research activities to become a nationwide leader. According to local economic authorities, two leading Asian biopharma research areas, in Singapore and Beijing, have been actively investing in genome analyzers to accelerate research activities; Okinawa hopes to be competitive in Asia as well.(Click here for more-Japanese language



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts